Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has been given an average recommendation of “Buy” by the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $42.71.

Several research analysts recently issued reports on PRTK shares. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price target on shares of Paratek Pharmaceuticals in a research report on Wednesday, August 23rd. Raymond James Financial reiterated a “strong-buy” rating and set a $36.00 price target on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Finally, Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Iguana Healthcare Management LLC acquired a new position in Paratek Pharmaceuticals during the 3rd quarter worth about $879,000. Belpointe Asset Management LLC acquired a new position in Paratek Pharmaceuticals during the 3rd quarter valued at about $228,000. Davidson Kempner Capital Management LP acquired a new position in Paratek Pharmaceuticals during the 3rd quarter valued at about $6,727,000. Highbridge Capital Management LLC acquired a new position in Paratek Pharmaceuticals during the 3rd quarter valued at about $5,285,000. Finally, Perceptive Advisors LLC acquired a new position in Paratek Pharmaceuticals during the 3rd quarter valued at about $532,000. Institutional investors and hedge funds own 84.30% of the company’s stock.

Shares of Paratek Pharmaceuticals (PRTK) opened at $17.90 on Thursday. Paratek Pharmaceuticals has a 52 week low of $13.15 and a 52 week high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/14/paratek-pharmaceuticals-inc-prtk-given-consensus-recommendation-of-buy-by-analysts.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.